Joensuu, Heikki
Blay, Jean-Yves
Comandone, Alessandro
Martin-Broto, Javier
Fumagalli, Elena
Grignani, Giovanni
Del Muro, Xavier Garcia
Adenis, Antoine
Valverde, Claudia
Pousa, Antonio Lopez
Bouché, Olivier
Italiano, Antoine
Bauer, Sebastian
Barone, Carlo
Weiss, Claudia
Crippa, Stefania
Camozzi, Maura
Castellana, Ramon
Le Cesne, Axel
Article History
Received: 7 April 2017
Revised: 4 July 2017
Accepted: 31 July 2017
First Online: 29 August 2017
Competing interests
: HJ receives honoraria for consultancy with Blueprint Medicines, Ariad Pharmaceuticals, and Orion Pharma. J-YB reports grants and personal fees from Novartis, grants and personal fees from Bayer, grants and personal fees from Roche, and grants and personal fees from Pfizer, outside the submitted work. AC has nothing to disclose. JM-B serves on the advisory board of Novartis, outside of the submitted work. EF has nothing to disclose. GG reports personal fees from Bayer, personal fees from Novartis, and personal fees from Pfizer, outside the submitted work. XGDM reports advisory role and receiving funding for research from Pfizer and Bayer. AA reports personal fees from Novartis, outside the submitted work. CV reports personal fees from Novartis, personal fees from Bayer, personal fees from Lilly, and personal fees from Pfizer, outside the submitted work. ALP has nothing to disclose. OB reports grants from Novartis, during the conduct of the study; personal fees from Novartis, personal fees from Roche, personal fees from Merck, personal fees from Lilly, and personal fees from Hospira, outside the submitted work. AI has nothing to disclose. SB reports grants and other from Novartis, grants from Blueprint Medicine, grants from Ariad, other from Bayer, other from Pfizer, other from Lilly, during the conduct of the study. CB reports grants from Novartis, outside the submitted work. CW, SC, MC, and RC are Novartis employees. ALC reports personal fees from Pfizer, personal fees from Pharmamar, personal fees from Amgen, personal fees from Lilly, and personal fees from Novartis-GSK, outside the submitted work.